tetano
Editor, Senior Moderator
Future Sci OA
. 2021 May 11;7(7):FSO713.
doi: 10.2144/fsoa-2021-0036. eCollection 2021 Aug.
Mortality rate and biomarker expression within COVID-19 patients who develop acute ischemic stroke: a systematic review and meta-analysis
Ahmed Yassin[SUP] 1 [/SUP], Ansam Ghzawi[SUP] 2 [/SUP], Abdel-Hameed Al-Mistarehi[SUP] 3 [/SUP], Khalid El-Salem[SUP] 1 [/SUP], Amira Y Benmelouka[SUP] 4 [/SUP], Ahmed M Sherif[SUP] 5 [/SUP], Nesrine BenhadjDahman[SUP] 6 [/SUP], Nameer AlAdamat[SUP] 7 [/SUP], Amine Jemel[SUP] 8 [/SUP], Ahmed Negida[SUP] 5 9 [/SUP], Mohamed Abdelmonem[SUP] 10 [/SUP]
Affiliations
Abstract
Objective: To describe the mortality difference between acute ischemic stroke (AIS) and non-AIS groups within COVID-19 patients.
Materials & methods: We included observational studies through September 2020 that categorized COVID-19 patients into two groups (with and without AIS).
Results: Eight studies with a total sample size of 19,399 COVID-19 patients were included. The pooled risk difference showed that patients with COVID-19 who developed AIS had significantly higher mortality than those without AIS by a risk difference of 24% (95% CI: 0.10-0.39; p = 0.001). In two studies, the COVID-19+AIS group had significantly higher lymphocytes, procalcitonin and creatinine levels.
Conclusion: Developing AIS significantly adds to the mortality of COVID-19. Timely interventions to manage those patients are strongly recommended.
Keywords: COVID-19; biomarkers; coronavirus; ischemic stroke; mortality rate; stroke.
. 2021 May 11;7(7):FSO713.
doi: 10.2144/fsoa-2021-0036. eCollection 2021 Aug.
Mortality rate and biomarker expression within COVID-19 patients who develop acute ischemic stroke: a systematic review and meta-analysis
Ahmed Yassin[SUP] 1 [/SUP], Ansam Ghzawi[SUP] 2 [/SUP], Abdel-Hameed Al-Mistarehi[SUP] 3 [/SUP], Khalid El-Salem[SUP] 1 [/SUP], Amira Y Benmelouka[SUP] 4 [/SUP], Ahmed M Sherif[SUP] 5 [/SUP], Nesrine BenhadjDahman[SUP] 6 [/SUP], Nameer AlAdamat[SUP] 7 [/SUP], Amine Jemel[SUP] 8 [/SUP], Ahmed Negida[SUP] 5 9 [/SUP], Mohamed Abdelmonem[SUP] 10 [/SUP]
Affiliations
- PMID: 34254031
- PMCID: PMC8114837
- DOI: 10.2144/fsoa-2021-0036
Abstract
Objective: To describe the mortality difference between acute ischemic stroke (AIS) and non-AIS groups within COVID-19 patients.
Materials & methods: We included observational studies through September 2020 that categorized COVID-19 patients into two groups (with and without AIS).
Results: Eight studies with a total sample size of 19,399 COVID-19 patients were included. The pooled risk difference showed that patients with COVID-19 who developed AIS had significantly higher mortality than those without AIS by a risk difference of 24% (95% CI: 0.10-0.39; p = 0.001). In two studies, the COVID-19+AIS group had significantly higher lymphocytes, procalcitonin and creatinine levels.
Conclusion: Developing AIS significantly adds to the mortality of COVID-19. Timely interventions to manage those patients are strongly recommended.
Keywords: COVID-19; biomarkers; coronavirus; ischemic stroke; mortality rate; stroke.